Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1048

1.

High-flow nasal cannula oxygen therapy obscures severe respiration depression, providing an illusion of safety.

Horiuchi A, Graham DY.

Gastrointest Endosc. 2020 Mar;91(3):720-721. doi: 10.1016/j.gie.2019.10.007. No abstract available.

PMID:
32087904
2.

Microbiome and Gastric Cancer.

Engstrand L, Graham DY.

Dig Dis Sci. 2020 Mar;65(3):865-873. doi: 10.1007/s10620-020-06101-z. Review.

PMID:
32040665
3.

14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.

Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham DY, Lu H.

Dig Dis Sci. 2020 Feb 4. doi: 10.1007/s10620-020-06115-7. [Epub ahead of print]

PMID:
32020360
4.

Bile acids and ceramide overcome the entry restriction for GII.3 human norovirus replication in human intestinal enteroids.

Murakami K, Tenge VR, Karandikar UC, Lin SC, Ramani S, Ettayebi K, Crawford SE, Zeng XL, Neill FH, Ayyar BV, Katayama K, Graham DY, Bieberich E, Atmar RL, Estes MK.

Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1700-1710. doi: 10.1073/pnas.1910138117. Epub 2020 Jan 2.

PMID:
31896578
5.

No Barrett's-No Cancer: A Proposed New Paradigm for Prevention of Esophageal Adenocarcinoma.

Graham DY, Tan MC.

J Clin Gastroenterol. 2020 Feb;54(2):136-143. doi: 10.1097/MCG.0000000000001298.

PMID:
31851107
6.

Susceptibility-guided therapy for Helicobacter pylori infection treatment failures.

Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q, Song Y, Li X, Graham DY, Lu H.

Therap Adv Gastroenterol. 2019 Sep 9;12:1756284819874922. doi: 10.1177/1756284819874922. eCollection 2019.

7.

Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.

Dore MP, Bibbò S, Loria M, Salis R, Manca A, Pes GM, Graham DY.

Helicobacter. 2019 Dec;24(6):e12659. doi: 10.1111/hel.12659. Epub 2019 Sep 9.

PMID:
31502382
8.

Rational Use of Pancreatic Enzymes for Pancreatic Insufficiency and Pancreatic Pain.

Ketwaroo GA, Graham DY.

Adv Exp Med Biol. 2019;1148:323-343. doi: 10.1007/978-981-13-7709-9_14. Review.

9.

Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020.

Tan MC, Graham DY.

Gastrointest Endosc. 2019 Sep;90(3):457-460. doi: 10.1016/j.gie.2019.05.034. No abstract available.

10.

Diagnosis: gastric intestinal metaplasia - what to do next?

Graham DY, Rugge M, Genta RM.

Curr Opin Gastroenterol. 2019 Nov;35(6):535-543. doi: 10.1097/MOG.0000000000000576.

PMID:
31415250
11.

Helicobacter pylori Infection.

Graham DY, Dang BN, El-Serag HB.

N Engl J Med. 2019 Aug 8;381(6):587-588. doi: 10.1056/NEJMc1905439. No abstract available.

PMID:
31390511
12.

Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges.

Estes MK, Ettayebi K, Tenge VR, Murakami K, Karandikar U, Lin SC, Ayyar BV, Cortes-Penfield NW, Haga K, Neill FH, Opekun AR, Broughman JR, Zeng XL, Blutt SE, Crawford SE, Ramani S, Graham DY, Atmar RL.

Viruses. 2019 Jul 11;11(7). pii: E638. doi: 10.3390/v11070638. Review.

13.

Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply.

Lu H, Graham DY.

Aliment Pharmacol Ther. 2019 Aug;50(3):332. doi: 10.1111/apt.15373. No abstract available.

PMID:
31313359
14.

Rofecoxib and Clinically Significant Gastrointestinal Events: Response.

Graham DY, Jewell NP, Chan FKL.

Am J Med Sci. 2019 Sep;358(3):e9-e10. doi: 10.1097/MAJ.0000000000000222. Epub 2019 Jul 10. No abstract available.

PMID:
31301755
15.

Dietary quality and the colonic mucosa-associated gut microbiome in humans.

Liu Y, Ajami NJ, El-Serag HB, Hair C, Graham DY, White DL, Chen L, Wang Z, Plew S, Kramer J, Cole R, Hernaez R, Hou J, Husain N, Jarbrink-Sehgal ME, Kanwal F, Ketwaroo G, Natarajan Y, Shah R, Velez M, Mallepally N, Petrosino JF, Jiao L.

Am J Clin Nutr. 2019 Sep 1;110(3):701-712. doi: 10.1093/ajcn/nqz139.

PMID:
31291462
16.

Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging.

Rugge M, Sacchi D, Graham DY, Genta RM.

Gut. 2019 Jun 11. pii: gutjnl-2019-319107. doi: 10.1136/gutjnl-2019-319107. [Epub ahead of print] No abstract available.

PMID:
31186295
17.

High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.

Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, Lu H.

Helicobacter. 2019 Aug;24(4):e12596. doi: 10.1111/hel.12596. Epub 2019 May 20.

PMID:
31111580
18.

Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor.

Dore MP, Bibbò S, Pes GM, Francavilla R, Graham DY.

Can J Infect Dis Med Microbiol. 2019 Apr 1;2019:3409820. doi: 10.1155/2019/3409820. eCollection 2019.

19.

Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.

Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H.

Aliment Pharmacol Ther. 2019 Jun;49(11):1385-1394. doi: 10.1111/apt.15273. Epub 2019 Apr 24.

PMID:
31020673
20.

Current and Future Treatment of Helicobacter pylori Infections.

Matsumoto H, Shiotani A, Graham DY.

Adv Exp Med Biol. 2019;1149:211-225. doi: 10.1007/5584_2019_367. Review.

21.

Changes of tight junction and interleukin-8 expression using a human gastroid monolayer model of Helicobacter pylori infection.

Uotani T, Murakami K, Uchida T, Tanaka S, Nagashima H, Zeng XL, Akada J, Estes MK, Graham DY, Yamaoka Y.

Helicobacter. 2019 Jun;24(3):e12583. doi: 10.1111/hel.12583. Epub 2019 Apr 5.

PMID:
30950121
22.

Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon.

Gurwara S, Ajami NJ, Jang A, Hessel FC, Chen L, Plew S, Wang Z, Graham DY, Hair C, White DL, Kramer J, Kourkoumpetis T, Hoffman K, Cole R, Hou J, Husain N, Jarbrink-Sehgal M, Hernaez R, Kanwal F, Ketwaroo G, Shah R, Velez M, Natarajan Y, El-Serag HB, Petrosino JF, Jiao L.

Nutrients. 2019 Mar 13;11(3). pii: E613. doi: 10.3390/nu11030613.

23.

Pantoprazole in Patients in the ICU.

Tan MC, Tansel A, Graham DY.

N Engl J Med. 2019 Mar 7;380(10):984. doi: 10.1056/NEJMc1900206. No abstract available.

PMID:
30855751
24.

The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal.

Wu JY, Lee YC, Graham DY.

Expert Rev Gastroenterol Hepatol. 2019 Jan;13(1):17-24. doi: 10.1080/17474124.2019.1542299. Epub 2018 Nov 13. Review.

25.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1420. doi: 10.1016/j.cgh.2019.01.039. Epub 2019 Jan 30. No abstract available.

PMID:
30710706
26.

Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model.

Ihekweazu FD, Fofanova TY, Queliza K, Nagy-Szakal D, Stewart CJ, Engevik MA, Hulten KG, Tatevian N, Graham DY, Versalovic J, Petrosino JF, Kellermayer R.

Gut Microbes. 2019;10(4):504-520. doi: 10.1080/19490976.2018.1560753. Epub 2019 Jan 21.

27.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):2005-2006. doi: 10.1016/j.cgh.2018.08.035. No abstract available.

28.

Reply.

El-Serag HB, Graham DY.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):2004. doi: 10.1016/j.cgh.2018.08.031. No abstract available.

29.

Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.

Graham DY, Lu H, Dore MP.

Helicobacter. 2019 Feb;24(1):e12554. doi: 10.1111/hel.12554. Epub 2018 Nov 15.

30.

Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?

Leow AH, Azmi AN, Loke MF, Vadivelu J, Graham DY, Goh KL.

J Dig Dis. 2018 Nov;19(11):674-677. doi: 10.1111/1751-2980.12679. Epub 2018 Nov 8.

PMID:
30307122
31.

Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything?

Graham DY.

Dig Dis Sci. 2019 Jan;64(1):4-6. doi: 10.1007/s10620-018-5288-9. No abstract available.

32.

Guilt by association: intestinal metaplasia does not progress to gastric cancer.

Graham DY, Zou WY.

Curr Opin Gastroenterol. 2018 Nov;34(6):458-464. doi: 10.1097/MOG.0000000000000472. Review.

33.

Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.

Graham DY, Dore MP, Lu H.

Expert Rev Anti Infect Ther. 2018 Sep;16(9):679-687. doi: 10.1080/14787210.2018.1511427. Epub 2018 Aug 23. Review.

34.

Enzyme therapy for functional bowel disease-like post-prandial distress.

Graham DY, Ketwaroo GA, Money ME, Opekun AR.

J Dig Dis. 2018 Nov;19(11):650-656. doi: 10.1111/1751-2980.12655. Epub 2018 Sep 21. Review.

35.

Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: A mini review.

Graham DY, Miftahussurur M.

J Adv Res. 2018 Jan 31;13:51-57. doi: 10.1016/j.jare.2018.01.006. eCollection 2018 Sep. Review.

36.

Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.

Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-Thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. Epub 2018 Jul 2.

PMID:
30042064
37.

Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.

Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E.

Gastroenterology. 2018 Nov;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007. Epub 2018 Jul 7. Review.

38.

Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply.

Yeomans ND, Graham DY.

Aliment Pharmacol Ther. 2018 Jun;47(11):1546-1547. doi: 10.1111/apt.14656. No abstract available.

39.

Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.

Reed GW, Abdallah MS, Shao M, Wolski K, Wisniewski L, Yeomans N, Lüscher TF, Borer JS, Graham DY, Husni ME, Solomon DH, Libby P, Menon V, Lincoff AM, Nissen SE.

J Am Coll Cardiol. 2018 Apr 24;71(16):1741-1751. doi: 10.1016/j.jacc.2018.02.036.

40.

Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis.

Wang Z, Graham DY, Khan A, Balakrishnan M, Abrams HR, El-Serag HB, Thrift AP.

Int J Epidemiol. 2018 Jun 1;47(3):966-975. doi: 10.1093/ije/dyy055.

41.

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.

Yeomans ND, Graham DY, Husni ME, Solomon DH, Stevens T, Vargo J, Wang Q, Wisniewski LM, Wolski KE, Borer JS, Libby P, Lincoff AM, Lüscher TF, Bao W, Walker C, Nissen SE; PRECISION investigators.

Aliment Pharmacol Ther. 2018 Jun;47(11):1453-1463. doi: 10.1111/apt.14610. Epub 2018 Apr 17.

42.

Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial.

Hsu PI, Tsay FW, Graham DY, Tsai TJ, Tsai KW, Kao JY, Peng NJ, Kuo CH, Kao SS, Wang HM, Lin TF, Wu DC; Taiwan Acid-related Disease (TARD) Study Group.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1427-1433. doi: 10.1016/j.cgh.2018.03.031. Epub 2018 Mar 31.

PMID:
29609070
43.

Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer.

Tan MC, Graham DY.

BMJ Evid Based Med. 2018 Jun;23(3):111-112. doi: 10.1136/bmjebm-2018-110935. Epub 2018 Mar 29. Review. No abstract available.

44.

Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States.

El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002.e6. doi: 10.1016/j.cgh.2018.03.013. Epub 2018 Mar 17. Erratum in: Clin Gastroenterol Hepatol. 2019 Mar;17(4):801. Crowe, Sheila [corrected to Crowe, Sheila E].

45.

Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals.

Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, Chen L, Wong ICK, Graham DY.

Gastroenterology. 2018 Jul;155(1):67-75. doi: 10.1053/j.gastro.2018.03.028. Epub 2018 Mar 14.

46.

An Investigation into the Recent Increase in Gastric Cancer in the USA.

Balakrishnan M, George R, Sharma A, Graham DY, Malaty HM.

Dig Dis Sci. 2018 Jun;63(6):1613-1619. doi: 10.1007/s10620-018-5012-9. Epub 2018 Mar 15.

47.

Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial.

Yeomans ND, Graham DY, Wang Q, Wolski K, Borer J, Husni EM, Libby P, Lincoff MA, Lüscher T, Wisniewski LM, Bao W, Walker C, Nissen SE.

Am J Gastroenterol. 2018 Jul;113(7):1053-1054. doi: 10.1038/s41395-018-0051-6. No abstract available.

PMID:
29535414
48.

Brief report: Lactobacillus bulgaricus GLB44 (Proviotic ) plus esomeprazole for Helicobacter pylori eradication: A pilot study.

Opekun AR, Gonzales SA, Al-Saadi MA, Graham DY.

Helicobacter. 2018 Apr;23(2):e12476. doi: 10.1111/hel.12476. Epub 2018 Mar 4.

49.

Editorial: Helicobacter pylori and gastric cancer in Alaskan Natives: Time to stop studying H. pylori and to eradicate it.

Lee YC, Asaka M, Graham DY.

Helicobacter. 2018 Jun;23(3):e12478. doi: 10.1111/hel.12478. Epub 2018 Mar 2. No abstract available.

50.

Update on the Use of Vonoprazan: A Competitive Acid Blocker.

Graham DY, Dore MP.

Gastroenterology. 2018 Feb;154(3):462-466. doi: 10.1053/j.gastro.2018.01.018. Epub 2018 Jan 11. No abstract available.

PMID:
29337157

Supplemental Content

Loading ...
Support Center